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Background: Several studies have investigated the factors associated with adherence to 
antidepressants, with inconsistent conclusions. However, no similar study has investigated 
this issue among patients diagnosed with major depressive disorder in Saudi Arabia. The aim 
of this study is to explore patients’ adherence to antidepressant medications, and the factors 
associated with adherence.
Methods: A non-experimental cross-sectional design was used to measure adherence to anti-
depressants among major depressive disorder patients, and the factors associated with adher-
ence. The patients were recruited from the outpatient clinic at the Al-Amal Complex for Mental 
Health in Riyadh, Saudi Arabia, between August 2013 and January 2014. Eligible participants 
met with one of the research coordinators for assessment of their adherence. Adherence was 
investigated indirectly by use of the Morisky Medication Adherence Scale, and patients’ beliefs 
were assessed through the Beliefs about Medicine Questionnaire. Information about the severity 
of their depression, demographics, and other study variables were collected.
Results: A total of 403 patients met the inclusion criteria and participated in the study. Of those, 
203 (50.37%) were females, while the remaining 200 (49.6%) were males. There was an aver-
age age of 39 years (standard deviation, ±11 years). Half of the patients (52.9%) reported low 
adherence to their antidepressant medication, with statistically significant differences between 
the low adherence and high adherence scores relating to sex, age, and duration of illness. 
Conclusion: Low medication adherence is a common problem among major depressive disorder 
patients in Saudi Arabia. Medication-taking behavior among depressed patients is influenced 
by several factors, mainly patients’ beliefs regarding antidepressants. This study has improved 
the understanding of the factors associated with adherence to antidepressants. 
Keywords: patient compliance, predictors, antidepressants, patients’ beliefs, depression, 
psychiatry 
Introduction
Adherence to medications is an essential step in the management of chronic diseases.1,2 
Adherence has been defined in different ways; the World Health Organization defines 
it as “the extent to which a person’s behaviour, taking medication, following a diet, 
and/or executing lifestyle changes, corresponds with agreed recommendations from a 
healthcare provider”.2 Non-adherence could be intentional or unintentional behavior;3 
if a patient does not take the medicine either because of forgetfulness or lack of access, 
this type of non-adherence is unintentional. In contrast, if the patient does not follow 
the prescription because of his or her personal beliefs or evaluation of the medicine, 
then it is called intentional non-adherence.3 
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Major depressive disorder is a major public health chal-
lenge due to its high prevalence, it is estimated to affect 
15% of the general population, and is being seen as a global 
disease burden.4 Major depressive disorder is one of the 
most disabling diseases, disrupting daily life, activities, 
and work. It is believed that major depressive disorder will 
become the second largest cause of disease burden in the 
next two decades.5,6 Major depressive disorder is also a com-
mon health problem in Saudi Arabia, where the prevalence 
is increasing. A previous study in Saudi Arabia estimated 
the prevalence of depression at 18%.7 The World Health 
Organization estimates that 50% of all depression patients 
have not been treated, and it is therefore expected that anti-
depressant use and other treatment options will increase on 
a global level.8
Although antidepressant medications are proven to be 
effective, many patients do not receive an adequate dosage 
for an adequate duration, and the medication’s effective-
ness is further reduced due to non-adherence.9 National and 
international therapeutic guidelines stress the importance 
of continuing antidepressants for at least 9 months.10,11 It 
has been found that 28% of patients discontinue medica-
tion after 1 month, and between 44% and 52% of patients 
discontinue medication after 3 months.10,12 Data from 
the Gulf countries revealed that 88% of Kuwaiti patients 
with major depressive disorder are non-adherent to their 
antidepressant medications.13–15 Unfortunately, there are 
no data from Saudi Arabia regarding patients’ adherence 
to antidepressants, and one cross-sectional study reported 
that only 60% of depressed patients adhere to their psy-
chiatric clinic visits.16 Few studies from Saudi Arabia have 
investigated adherence to medication and factors associ-
ated with adherence among non-psychiatric, chronically 
ill patients.17,18 
Several studies have investigated the factors associated 
with adherence to antidepressant medication,6,9,19,20 and the 
results from a recent review show that factors associated 
with adherence to antidepressants and sociodemographic 
indictors are inconsistent.6 Certain factors have been iden-
tified as predictors of adherence to antidepressant medi-
cation, including sociodemographic factors, educational 
level, clinical factors (eg, severity of symptoms), quality 
of life, and side effects.6,9 In addition, evidence showed that 
patients’ beliefs about antidepressant medication can affect 
patients’ adherence.21 Based on similar factors, Horne’s 
Theoretical Model of medication can be used to identify 
patients’ behaviors, showing that they depend upon patients’ 
perceived need for treatment (necessity) and on concerns 
about the possibly harmful effects of the medication.22 
According to this theory, if the necessity for treatment is 
greater than the concern about adverse effects, the adherence 
will be strong; if the concerns are greater than the necessity, 
then the adherence will be poor.21 Furthermore, the impact 
of beliefs on adherence varies according to culture.23 While 
beliefs about medication have been studied intensely, little 
is known about depressed patients’ beliefs toward antide-
pressants in Saudi Arabia, and whether their beliefs affect 
their medication use behavior. Furthermore, little is known 
about the influence of other factors on medication use in 
Saudi Arabia. 
The purpose of this study was to explore patients’ adher-
ence to antidepressant medication, and the factors associated 
with adherence among depressed patients.
Methods
A non-experimental cross-sectional design was used to mea-
sure adherence to antidepressants among major depressive 
disorder patients, and to explore the factors associated with 
adherence. Patients were recruited from outpatient clinics of 
the Al Amal Complex for Mental Health in Riyadh, Saudi 
Arabia between August 2013 and January 2014. Al Amal 
Complex has 500 beds and provides psychiatric care to 
the whole population of the capital city (Riyadh) of Saudi 
Arabia. 
study population
All patients meeting the following inclusion criteria were 
invited sequentially to participate after a briefing about the 
objectives of the study: 1) patients within the age range of 
18 to 60 years; 2) patients diagnosed with major depressive 
disorder, according to the Diagnostic and Statistical Manual 
of Mental Disorders; 3) patients with a history of disease for 
at least 6 months; and 4) patients who were prescribed at least 
one antidepressant medication. Patients having history of 
psychosis, bipolar disorder, drug dependency, or who were 
prescribed concomitant medications other than antidepres-
sants were excluded from the study. A written consent was 
sought from the patients, and eligible participants met with 
one of the research coordinators for assessment of adherence, 
the patient’s beliefs, severity of symptoms, demographics, 
and other study variables. 
ethical considerations
Ethical approval was granted by the local training and 
research committee at Al Amal hospital, Riyadh, Saudi 
Arabia.
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statistical methods and sample size
To calculate the sample size, it was taken into account that 
the average percentage of low adherence among depressed 
patients is 52%.12,16 With a confidence level of 95%, a total 
of 401 patients was needed to conduct the study. Descrip-
tive and comparative statistics were carried out using the 
Statistical Package for Social Sciences, version 17 (SPSS 
Inc., Chicago, IL, USA). Analyses of covariance were 
conducted to assess differences in medication adherence, 
beliefs, and depression severity between groups. Indepen-
dent samples t-test was conducted to compare overall mean 
adherence between groups. To investigate the relation and 
correlation between factors and adherence, both a Pearson 
correlation coefficient and a multiple regression (stepwise 
method) were used. 
adherence and medication beliefs 
Patients’ adherence was assessed by an Arabic version of the 
Morisky Medication Adherence Scale (MMAS),24 a well-
validated instrument developed by Morisky et al.25–28 MMAS 
has good validity and reliability, has also been proven to be a 
useful screening technique for antidepressant medications,29 
and has been validated on other Arabic patients suffering 
from chronic diseases.24,30,31 MMAS consists of eight items 
that address specific medication-taking behavior and adher-
ence. The first seven items have dichotomous responses (yes/
no), and they are formulated in a way to avoid an acquies-
cence bias. The total score of MMAS ranges from 0 to 8, 
with higher scores representing better adherence. Those who 
score less than 6 are considered to have poor adherence, and 
those who score 6 or more are considered to be high adherers. 
Written permission to use the questionnaire was obtained 
from its authors.
Specific and general beliefs of patients were assessed 
by using the Arabic version of the Beliefs about Medicine 
Questionnaire (BMQ-Specific and BMQ-General),24 a self-
reporting measure of proven validity, reliability, and psy-
chometric capability, with both general medical patients and 
with depressed patients.21,32,33 The BMQ-Specific contains 
two parts, “Specific Necessity”, which evaluates patients’ 
views about the necessity and importance of their medication, 
and “Specific Concerns”, which questions patients’ beliefs 
about the potential harm and adverse effects of their own 
medications. Each part of the questionnaire has a potential 
score ranging from five to 25. The BMQ-General also has 
two parts, “General-Harm”, which measures beliefs that 
medicines in general are harmful, addictive, or poisonous, 
while the second part, “General-Overuse” measures beliefs 
that medicines in general are over-used by doctors.33 Again, 
written permission was obtained from the original author.
Results
A total of 403 patients met the inclusion criteria and par-
ticipated in this study. Patients’ characteristics are shown in 
Table 1. Exactly 203 patients, representing 50.4% of the total 
study sample, were females, and the remaining 200 patients 
(49.6%) were males. Participants’ ages ranged from 18 to 
60 years, with an average of 39 years (standard deviation 
[SD], ±11 years). A proportion or 36.9% of the participants 
were uneducated, or had only finished a few years of primary 
school. The majority of the participants (82.4%) were using 
one antidepressant medication, with an average illness dura-
tion of more than 5 years.
Almost half of the patients (52.9%) reported low 
adherence to their antidepressant medication. The average 
MMAS score was 5.23, and details of patients’ self-reported 
adherence behavior, according to the MMAS, are shown in 
Table 2. A statistically significant difference in adherence 
level is shown in favor of the male sex, older age, patients 
with a shorter duration of illness, and those having more than 
three follow-up visits with a psychiatric clinic per year, shown 
in detail in Table 1. On the other hand, the number of medica-
tions per prescription, and the pharmacological group of the 
antidepressant medication, were not significantly associated 
with adherence level to antidepressant medication. 
Both low- and high-adherence groups scored high in the 
necessity beliefs, with scores of 18.02 (SD, ±3.91 points) 
and 18.32 (SD, ±3.9 points), respectively, with no statisti-
cally significant difference. In contrast, patients with high 
adherence had significantly lower levels of concern about 
antidepressant medication, and significantly lower harm-
ful beliefs. In addition, high-adherence patients reported 
less severity of depression on the Montgomery–Åsberg 
 Depression Scale (Table 3).
Using Pearson’s correlation coefficient to examine 
the relationship between factors and adherence behavior 
resulted in a negative association between adherence and 
specific belief concerns. There was also a negative associa-
tion between general overuse belief, general harm belief and 
severity of depression (measured by the Montgomery–Åsberg 
Depression Scale), as shown in Table 4. On the other hand, 
there was no positive association between the adherence 
score and the other proposed factors. However, when using 
the multiple linear regression stepwise method for certain 
variables, dependent on the adherence scores and after adjust-
ing for other covariables, it was found that belief concerns 
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Table 1 characteristics of study participants and their level of adherence
Factor Frequency (%) Adherence, mean Standard deviation
Sex 
Male* 200 (49.6) 5.72 ±1.84
Female 203 (50.4) 4.75 ±1.95
Age (years)
18–30 102 (25.1) 5.55 ±1.73
31–40 120 (29.9) 4.77 ±2.10
41–50 102 (25.1) 4.65 ±1.95
51–60* 80 (19.8) 6.09 ±1.66
Education level
No formal education 90 (22.5) 4.86 ±2.02
Primary 58 (14.4) 5.42 ±1.84
intermediate 80 (19.8) 4.84 ±2.02
secondary 130 (32.1) 5.60 ±2.03
college/bachelor’s degree 45 (11.2) 5.06 ±1.52
Number of antidepressant drugs currently taken
One 331 (82.3) 5.19 ±1.98
Two 72 (17.7) 5.24 ±1.90
Number of clinic visits per year
One 28 (7.0) 4.25 ±1.87
Two 41 (10.2) 5.09 ±1.92
Three 149 (36.9) 4.67 ±1.98
Four* 185 (46.0) 5.79 ±1.81
Illness duration
Three years or less** 114 (28.3) 5.57 ±1.80
Between 3 and 6 years 92 (23.0) 5.52 ±1.89
Between 6 and 9 years 172 (42.8) 4.95 ±1.96
More than 9 years 23 (5.9) 3.95 ±2.39
Notes: student’s t-test was used for the differences in the characteristics of the study according to the level of adherence. *Significant at the P=0.001 level. **Significant at 
the P=0.05 level.
Table 2 Participants’ reported adherence behavior by MMas-8
Item Percentage (%) of  
patients who answered yes
When you travel or leave home, do you sometimes forget to bring along your medication? 51.3
People sometimes miss taking their medications for reasons other than forgetting. Thinking over the past two 
weeks, were there any days when you did not take your medicine?
48.1
have you ever cut back or stopped taking your medication without telling your doctor, because you felt worse 
when you took it? 
46.8
Do you sometimes forget to take your medicine? 40.6
When you feel like your health condition is under control, do you sometimes stop taking your medicine? 39.0
Taking medication every day is a real inconvenience for some people. Do you ever feel hassled about sticking 
to your treatment plan?
31.0
How often do you have difficulty remembering to take all your medications?
Never
Once in a while
sometimes
Usually
all of the time
87.7
7
3.6
1.7
0
Abbreviation: MMas-8, eight-item Morisky Medication adherence scale.
(R=0.40; P0.001, R2=0.162) were the most important pre-
dictor associated with adherence to antidepressants; general 
harm and severity of depression in different levels of associa-
tion, were also associated with adherence to antidepressants, 
as shown in Table 5. 
Discussion
To the best of our knowledge, this is the first study to inves-
tigate factors associated with adherence among Saudi major 
depressive disorder patients, using a validated tool to measure 
patients’ adherence and beliefs. However, a limited study has 
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reported medication adherence among non-psychiatric Saudi 
patients, for example AlHewiti et al18 reported adherence and 
beliefs about medications among primary health care patients 
in Riyadh; also, Khan and et al34 reported adherence among 
diabetics attending primary health centers in the Al Hasa 
district, Saudi Arabia.
The current study indicated that the majority of patients 
with major depressive disorder reported low adherence 
(52.9%). These findings are similar to those of two other stud-
ies conducted on chronic diseases in Riyadh and the Al Hasa 
region of Saudi Arabia, both of which found low adherence 
to medication, in a range from 51% to 57.5%.18,34 
There were high specific necessity belief scores among 
patients in both the low- and high-adherence groups in the cur-
rent study, with a slightly higher score in the high-adherence 
group. The high-necessity belief scores were associated 
with the high average age of the population included in the 
study. This finding is also supported by another study.35 In 
the current study, adherence was found to be influenced by 
specific belief concerns, general harm, and overuse beliefs 
about antidepressant medications, all of which are similar to 
the findings of other studies.6,18
Low adherence to antidepressant medications and sever-
ity of depression had a negative correlation, with a signifi-
cance at the P=0.01 level, which is compatible with results 
of Roca et al36 and Russell et al;37 however, other studies did 
not find a relationship between adherence and severity of 
depression.6 This finding can be explained by an inverse 
causal association, suggesting that adherence to a treatment 
regimen may lead to a better clinical outcome.20 
Other factors associated with low adherence included 
younger age. This could reflect the fact that younger patients 
have had less experience with the disease and its medications. 
It is also possible that the more common side effects of weight 
gain and impaired sexual function are of particular concern 
to younger patients.20 On the other hand, the high adher-
ence scores among patients who have more follow-up visits 
with a psychiatrist per year could be related to the effect of 
physician–patient contact and the patient’s satisfaction.38
This study has a few limitations. First, the study design 
is cross-sectional and therefore cannot determine causation 
unless there is narrative evidence to support the findings; 
also, non-experimental design led us to recruit patients 
sequentially and non-randomly. Second, the use of self-
reporting scales alone is a limitation. However, all scales 
used in this study were selected carefully, relying on well-
proven tests already validated with Arabic patients.23,24 
Furthermore, patients who report low adherence are most 
likely to be truthful.18 Finally, the influence of the research-
ers during the collection of data from patients can lead to 
bias, but this is believed to have had a minimal effect on the 
study outcome.
Further studies are needed to examine the impact of 
interventions targeting those factors that have correlated 
with adherence to antidepressants. For example, specific 
belief concerns, general harm, and overuse beliefs about 
Table 3 Patients’ beliefs about antidepressants, the severity of their depression, and their level of adherence
Factor Low adherence (N=214) High adherence (N=189) t-value P-value
Mean Standard deviation Mean Standard deviation
general overuse 12.75 2.50 12.18 2.49 1.549 0.123
general harm* 11.74 2.67 10.11 2.45 4.319 0.000
Necessity beliefs 18.02 3.91 18.32 3.90 0.520 0.603
Belief concerns* 14.30 3.50 11.82 3.03 5.153 0.000
Montgomery–Åsberg Depression scale* 25.75 13.66 17.61 10.92 4.519 0.000
Note: *Significant at the P=0.001 level.
Abbreviation: N, number of patients.
Table 4 Multiple regression (stepwise method) for study of characteristics influencing adherence (model summary) 
r r2 β (unstandardized) β (standardized) t-value P-value 
(significance 
level)
Belief concerns 0.402 0.162 -0.157 -0.282 4.306 0.000  
(0.01)
general harm 0.472 0.223 –0.147 -0.201 3.027 0.003  
(0.01)
Montgomery–Åsberg  
Depression scale
0.527 0.278 -0.036 -0.242 3.805 0.000  
(0.01)
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antidepressants, and severity of depression, should all be 
further investigated.
Conclusion 
Low adherence is a common health problem among depressed 
patients in Saudi Arabia and is influenced, as explained by 
Horne’s theoretical model,33 by high belief concerns and high 
general harm beliefs regarding antidepressants. This study 
has improved the understanding of factors associated with 
adherence to antidepressants, and their relationship. This 
understanding should help caregivers and stakeholders to 
improve the management and clinical outcomes of depressed 
patients by addressing their medication-taking behavior using 
a systematic approach.
Disclosure
The authors report no conflicts of interest in this work.
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